Physician profile
Ruby Rs Kapadia
NPI 1134544307
$4,769.82
in general payments reported to CMS, 2019-2025
28 companies · $587 in 2025
The $587 reported for 2025 was more than what 83% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.95 · 2020: $82.15 · 2021: $361 · 2022: $1,325 · 2023: $1,085 · 2024: $1,289 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,837 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,837.26 |
| Education | $124.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $1,176.01 | 2022-2023 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $738.05 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $451.14 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $408.45 | 2021-2024 | |
| Braeburn INC. | $310.08 | 2024-2025 | Brixadi |
| Amgen INC. | $195.89 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $182.26 | 2019-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.74 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $124.76 | 2024 | Auvelity |
| Almatica Pharma LLC | $123.01 | 2022-2024 | Loreev Xr, Gralise, Teriparatide |
| Indivior INC. | $107.78 | 2021-2024 | Sublocade |
| Tolmar, INC. | $107.62 | 2023-2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $93.67 | 2021-2023 | Dificid, Pifeltro, Delstrigo |
| Clarus Therapeutics INC. | $84.23 | 2021 | |
| Pfizer INC. | $64.63 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $63.46 | 2021-2024 | Trintellix |
| Lundbeck LLC | $58.47 | 2025 | Rexulti |
| Novo Nordisk INC | $43.66 | 2019-2021 | |
| Exact Sciences Corporation | $43.07 | 2023-2024 | Cologuard Collection Kit |
| Acerus Pharmaceuticals Corporation | $41.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $41.21 | 2021-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $36.27 | 2025 | Rexulti |
| Astellas Pharma US INC | $31.10 | 2024 | Veozah |
| Antares Pharma, INC. | $15.00 | 2020 | |
| Neuronetics, INC. | $14.51 | 2023 | Neurostar Tms Therapy System |
| Viiv Healthcare Company | $14.50 | 2022 | |
| Protega Pharmaceutials INC | $14.16 | 2023 | Roxybond |
| Alfasigma USA, INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Kapadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.